Korea United Pharm, Approval of Phase 2 Clinical Trial Plan for COVID-19 Treatment View original image

[Asia Economy Reporter Hwang Yoon-joo] The Ministry of Food and Drug Safety announced on the 28th that it has approved the Phase 2 clinical trial plan to exploratively evaluate the efficacy and safety of the COVID-19 treatment candidate substance 'UI030' (active ingredients budesonide and formoterol) applied for by Korea United Pharm.


With this, the number of products under development with approved clinical trial plans for COVID-19 treatment in South Korea has increased to 14 items with 12 active ingredients.


UI030 is also being developed as an asthma treatment, and Korea United Pharm has conducted a Phase 1 clinical trial administering this drug to healthy individuals domestically.


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

Following the approval of this Phase 2 clinical trial, the company will explore whether the anti-inflammatory and bronchodilator effects have therapeutic benefits for COVID-19 patients.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing